The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Open accessAbstract
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States. It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacological treatment for MDD was discovered. Several monoamine-based pharmacological drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved. As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a number of studies have examined the glutamatergic systems as viable targets for the treatment of MDD. This review will provide a brief history on the development of clinically available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiology of MDD. Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD. The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD. However, compounds that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clinical trials. Thus, the clinical findings to date are encouraging and support the continued search for and the development of novel compounds that target glutamatergic mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 3×
“Females are two-to-three times more likely to be diagnosed with MDD as compared to their male counterparts regardless of age group (Kessler et al., 2012).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
The metabotropic glutamate receptors: Structure and functions
Pin, J.-P., & Duvoisin, R. (1995) · Neuropharmacology · doi:10.1016/0028-3908(94)00129-g · Cited by 2,266
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“342 TCAs have a common three-ring chemical structure, and the main TCAs are imipramine, amitriptyline, clomipramine, desipramine and doxepin.”
BackgroundZhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“The N-methyl-D-aspartate receptor antagonist, ketamine, is an effective antidepressant agent for treatment-resistant depression [6-14].”
Light Affects Mood and Learning through Distinct Retina-Brain Pathways
Fernandez, D. C., Fogerson, P. M., Lazzerini Ospri, L., Thomsen, M. B., Layne, R. M., Severin, D., Zhan, J., Singer, J. H., Kirkwood, A., Zhao, H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.004 · Cited by 505
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
Neuroinflammation in Bipolar Depression
Benedetti, F., Aggio, V., Pratesi, M. L., Greco, G., & Furlan, R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00071 · Cited by 274
The future of rodent models in depression research
Gururajan, A., Reif, A., Cryan, J. F., & Slattery, D. A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0221-6 · Cited by 269
Treating major depression with yoga: A prospective, randomized, controlled pilot trial
Prathikanti, S., Rivera, R., Cochran, A., Tungol, J. G., Fayazmanesh, N., & Weinmann, E. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173869 · Cited by 157
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Braslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Harris, M. G., Kazdin, A. E., Chiu, W. T., Sampson, N. A., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Altwaijri, Y., Andrade, L. H., Cardoso, G., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1107 · Cited by 100
Allostasis, action and affect in depression: Insights from the theory of constructed emotion
Shaffer, C., Westlin, C., Quigley, K. S., Whitfield-Gabrieli, S., & Barrett, L. F. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081219-115627 · Cited by 94
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Arabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
iPlasticity: Induced juvenile‐like plasticity in the adult brain as a mechanism of antidepressants
Umemori, J., Winkel, F., Didio, G., Llach Pou, M., & Castrén, E. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12683 · Cited by 80
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
Huang, Y.-J., Lane, H.-Y., & Lin, C.-H. (2017) · Neural Plasticity · doi:10.1155/2017/4605971 · Cited by 74
Taniguti, E. H., Ferreira, Y. S., Stupp, I. J. V., Fraga-Junior, E. B., Mendonça, C. B., Rossi, F. L., Ynoue, H. N., Doneda, D. L., Lopes, L., Lima, E., et al. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.02.034 · Cited by 62
Inoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
(2019) · PubMed Central · Cited by 37
Noradrenaline activation of hippocampal dopamine D 1 receptors promotes antidepressant effects
Kobayashi, K., Shikano, K., Kuroiwa, M., Horikawa, M., Ito, W., Nishi, A., Segi-Nishida, E., & Suzuki, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117903119 · Cited by 34
Stippl, A., Scheidegger, M., Aust, S., Herrera, A., Bajbouj, M., Gärtner, M., & Grimm, S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.028 · Cited by 29
Mechanisms Underlying the Antidepressant Effect of Acupuncture via the CaMK Signaling Pathway
Bai, L., Zhang, D., Cui, T.-T., Li, J.-F., Gao, Y.-Y., Wang, N.-Y., Jia, P.-L., Zhang, H.-Y., Sun, Z.-R., Zou, W., et al. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.563698 · Cited by 27
Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice
Hatamnejad, M. R., Baradaran Ghavami, S., Shirvani, M., Asghari Ahmadabad, M., Shahrokh, S., Farmani, M., Sherkat, G., Asadzadeh Aghdaei, H., & Zali, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980189 · Cited by 28
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction
Tizabi, Y., Getachew, B., Hauser, S. R., Tsytsarev, V., Manhães, A. C., & da Silva, V. D. A. (2024) · Brain Sciences · doi:10.3390/brainsci14060558 · Cited by 27
Efficacy of antidepressants: bias in randomized clinical trials and related issues
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1377070 · Cited by 20
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Serotonin is a common thread linking different classes of antidepressants
Witt, C. E., Mena, S., Holmes, J., Hersey, M., Buchanan, A. M., Parke, B., Saylor, R., Honan, L. E., Berger, S. N., Lumbreras, S., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.10.009 · Cited by 18
Evaluation of the antidepressive property of β-hydroxybutyrate in mice
Pan, S., Hu, P., You, Q., Chen, J., Wu, J., Zhang, Y., Cai, Z., Ye, T., Xu, X., Chen, Z., et al. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000535 · Cited by 12
Zolnoori, M., Fung, K. W., Fontelo, P., Kharrazi, H., Faiola, A., Wu, Y. S. S., Stoffel, V., & Patrick, T. (2018) · JMIR Mental Health · doi:10.2196/10726 · Cited by 11
Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Ma, X., Kim, H., Zhang, L., Chen, P., Wei, J., Cui, Y., Chen, L., Xu, Y., Zhang, J., Dai, Z., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04128-w
“Despite extensive research and a range of pharmacological and psychotherapeutic options, treatment ef fi - cacy remains limited; more than half of patients fail to achieve full remission with currently available therapies [1 – 3].”
Metadata
- Authors
- Hillhouse, T. M., & Porter, J. H.
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2015-02
- Volume
- 23
- Issue
- 1
- Pages
- 1-21
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2048175288
- Cited by
- 605
- References
- 171
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.